MétaCan
Menu
Retour à la cohorte
Enregistrement W3216457798 · doi:10.7939/r3-2dz6-3t18

Contribution of Ketone Oxidation on Energy Production in the Failing Heart

2021· article· en· W3216457798 sur OpenAlexaboutno aff
Simran Pherwani

Notice bibliographique

RevueUniversity of Alberta Library · 2021
Typearticle
Langueen
DomaineMedicine
ThématiqueCardiovascular Function and Risk Factors
Établissements canadiensnon disponible
Organismes subventionnairesnon disponible
Mots-clésProduction (economics)ChemistryEconomics

Résumé

récupéré en direct d'OpenAlex

One third of all deaths in Canada are due to cardiovascular diseases, including heart failure. Cardiovascular diseases have a considerable economic burden, and drastically impact the health and quality of life of Canadians. Heart failure (HF) is a clinical condition where the heart is unable to adequately pump blood throughout the body, limiting nutrient and 02 delivery. Individuals with type 2 diabetes (T2D) are at high risk of developing HF. A class of anti-diabetic drugs, sodium glucose co-transporter 2 inhibitors (SGLT2i), have recently been shown to improve HF outcomes in clinical trials with individuals with HF regardless of the presence of type 2 diabetes (T2D). SGLT2i are expressed in the proximal tubule of the kidney and are involved in 90% of the reabsorption of filtered glucose. SGLT2 inhibition prevents glucose reabsorption and reentry into the circulation, improving glycemic control. The EMPAREG-OUTCOMES trial in 2019 showed that the SGLT2i, empagliflozin, decreased hospitalization and deaths due to cardiovascular causes such as HF in T2D patients at high risk for cardiovascular events. The DAPA-HF trial in 2020 showed that the SGLT2i, dapagliflozin, also improved cardiac outcomes; however, in both the presence or absence of T2D. This was followed shortly after by the EMPEROR trial in 2021 which confirmed these observations with empagliflozin. However, it has not yet been fully established how exactly SGLT2i act to improve cardiac function, and the mechanisms responsible for their cardioprotective effects remain unclear. The failing heart exhibits a decrease in mitochondrial oxidative phosphorylation, namely glucose oxidation rates, resulting in decreased energy production in the heart. Increased evidence has shown that circulating ketones as well as cardiac ketone utilization increases in heart failure. Additionally, SGLT2i have been shown to increase circulating ketone levels. Therefore, we hypothesized that SGLT2i improve cardiac function by providing the failing heart with an extra source of fuel in the form of ketones. Thus, the purpose of this study was to determine whether increased energetics through providing ketones as an extra fuel to the failing heart is responsible for the improvement in cardiac function and cardiovascular outcomes seen in SGLT2i clinical trials, and to address a possible mechanism behind the cardioprotective effects. 8-week old C57BL6/N mice underwent a transverse aortic constriction (TAC) or sham surgery to induce pressure overload hypertrophy over 3 weeks, following which mice were randomized to receive either dapagliflozin (1mg/kg BW) or not in their drinking water for 4 weeks. Biweekly body weight and blood glucose and ketone measurements were taken. Echocardiography was done at 3 weeks and 6 weeks post surgery to assess cardiac function, and a glucose tolerance test (GTT) was done at the 6-week time point. After the 7-week protocol, mice were subjected to ex-vivo isolated working heart perfusions, where their hearts were perfused with radiolabelled Betahydroxybutyrate (BOHB), palmitate, or glucose to assess substrate oxidation and glycolytic rates. Hearts were perfused at physiological conditions of these substrates as well as concentrations seen following treatment (i.e. BOHB levels observed in vivo with Dapagliflozin treatment): this was 0.2 mM and 0.6 mM BOHB, respectively. Protein expression of ketone oxidation enzymes, as well as inflammation markers in the mouse heart were measured using immunoblotting. We did not observe an improvement in in vivo cardiac function; however, we did observe an increase in cardiac efficiency with DAPA treatment in HF, alongside increased ATP production due to increased glucose and BOHB oxidation rates. Additionally, we did not observe any significant improvement in circulating ketone levels with treatment, or in cardiac energy metabolism with dapagliflozin treatment at both 0.2 mM and 0.6 mM BOHB. Therefore, our results suggest that the beneficial cardiovascular effects of SGLT2i may not be due to fuel use and improved energetics as hypothesized, as we did not observe any significant changes in substrate oxidative rates with dapagliflozin. Since we observed a trend towards an increase in NLRP3/NALP3 inflammasome protein expression, we believe there is value in exploring the NLRP3/NALP3 inflammasome pathway as a potential mechanism through which SGLT2i may be acting.

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.

Comment cette classification a été obtenuedéplier

Prédiction distillée sur la base complète

Imitation des enseignants

Ni prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.

score de la tête « metaresearch » (Codex)0,000
score de la tête « metaresearch » (Gemma)0,000
Version: codex-gemma-dda1882f352aStatut de validation: machine_predicted_unvalidated
Catégories candidatesaucune
Catégories consensuellesaucune
DomaineSignal candidat: aucune · Signal consensuel: aucune
Devis d'étudeSignal candidat: Observationnel · Signal consensuel: Observationnel
GenreSignal candidat: Empirique · Signal consensuel: Empirique
Score de désaccord entre enseignants0,292
Score d'incertitude au seuil0,158

Scores Codex et Gemma par catégorie

CatégorieCodexGemma
Métarecherche0,0000,000
Méta-épidémiologie (sens strict)0,0000,000
Méta-épidémiologie (sens large)0,0000,000
Bibliométrie0,0000,000
Études des sciences et des technologies0,0000,000
Communication savante0,0000,000
Science ouverte0,0000,000
Intégrité de la recherche0,0000,000
Charge utile insuffisante (le modèle a refusé de juger)0,0000,000

Scores machine (provisoires)

Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.

Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.

Tête enseignante Opus0,007
Tête enseignante GPT0,184
Écart entre enseignants0,177 · la distance entre les deux têtes enseignantes sur ce seul travail
Statut de validationscore_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découle

Classification

machine, non validée

Prédiction automatique; un appel candidat d’une seule tête enseignante, pas un consensus.

Les modèles n’ont appliqué aucune catégorie : rien dans la taxonomie ne correspondait à ce travail.
Devis d'étudeObservationnel
Domainenon disponible
GenreEmpirique

Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».

En bref

Citations0
Publié2021
Routes d'admission1
Résumé présentoui

Explorer davantage

Même revueUniversity of Alberta LibraryMême sujetCardiovascular Function and Risk FactorsTravaux en français237 207